Introduction {#Sec1}
============

Coronaviruses are a single-stranded enveloped RNA virus belonging to the Coronaviridae family (beta genus type), have a diameter of 60--140 nm, known to cause respiratory infections in human \[[@CR1], [@CR2]\]. At the end of 2019, China has experienced an outbreak of a novel coronavirus that killed more than a thousand and infected over 7000 individuals within the first 50 days and later spread rapidly all over the world \[[@CR3]\]. At that time initially, it was named novel coronavirus 2019 (2019-nCoV) by the Chinese Center for Disease Control and Prevention, which was further renamed to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) by the World Health Organization (WHO) and the disease caused by this SARS-CoV-2 named as coronavirus disease 2019 (COVID-19) by WHO \[[@CR4]\]. It has around 70% similar genetic sequence with 2002--2003 pandemic severe acute respiratory syndrome coronavirus (SARS-CoV) \[[@CR5]\]. Fever, dry cough, and fatigue are identified as the common symptoms of the infections as well as prolonged prothrombin time and lymphopenia are identified as common characteristics of the infections \[[@CR6]\]. The transmission route for COVID-19 to humans is through bat and the intermediate host for transmission is still under research \[[@CR6]\], as the virus used an intermediate host to acquire a series of genetic mutations to infect humans effectively \[[@CR4]\]. The local transmission of COVID-19 occurred through respiratory droplets, saliva, feces, and urine from infected individuals \[[@CR4]\]. In March 2020, the WHO officially declared it as a global pandemic \[[@CR7]\]. As of 21st April 2020, 0.16 million deaths with COVID-19 have been reported among 2.4 million confirmed cases globally \[[@CR2]\].

Several clinical studies have reported cardiovascular diseases (CVD) as the most common cause of comorbidity in patients with COVID-19; also, a proportion of those patients became critically ill and dead \[[@CR8]\], besides, the disease itself is associated with CVD complications \[[@CR9]\]. As CVD complications can be a significant contributor to mortality among the patient with the disease, awareness of emergency clinicians becoming very vital \[[@CR7]\]. Studies also reported higher risk of a diabetic individual to get infected with the SARS-CoV-2 virus and having other complications or may die from the disease \[[@CR2]\].

In this study, we tried to cover the association of COVID-19 infection in individuals with CVD, DM, and their related complications associated with COVID-19 infection.

CVD and COVID-19 {#Sec2}
================

COVID-19 with Pre-existing CVD {#Sec3}
------------------------------

Severe symptoms of COVID-19 are more common in patients with pre-existing CVD when became infected; therefore, a large proportion of deaths from COVID-19 have resulted among those patients \[[@CR10]\]. A meta-analysis of 1527 patients with COVID-19 showed that patients with cardiac disease (16.4%) and hypertension (17.1%) were more likely to require intensive care \[[@CR7]\]. Another study conducted on 44,672 patients with COVID-19 showed that fatality rate is nearly five-fold higher in patients with pre-existing CVD compared to patients without CVD (10.5% vs. 2.3%) \[[@CR7]\]. In a study on 191 patients from Wuhan, China, 48% of patients had comorbidity (67% died), 30% of which had hypertension (48% died), and 8% of them had CVD (13% died) \[[@CR11]\]. Similar findings had been suggested by other studies that high risk of mortality in patients with pre-existing CVD \[[@CR6], [@CR8]--[@CR10]\]. Studies reported that patients with hypertension and CVD have higher expression of angiotensin-converting enzyme-2 (ACE2), which could be a potential reason for enhancing susceptibility of those patients to SARS-CoV-2, a possible mechanistic pathway of severity between COVID-19 and CVD (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR9]\]. Alongside, patients with CVD are more likely to have hypercoagulability due to increase level of D-dimer, which increases the risk of pulmonary embolism, therefore, hypoxia and heart failure \[[@CR8]\]. Also, in patients with the acute coronary syndrome (ACS), reduced cardiac function has been observed leading to myocardial ischemia, which might act as a factor to worsen the condition of patients with COVID-19 and may lead to death \[[@CR10]\].Fig. 1A possible mechanistic pathway of severity between CVD and COVID-19 and role of ACE2 in COVID-19

CVD Induced by COVID-19 {#Sec4}
-----------------------

Angiotensin-converting enzyme 2 (ACE2), a membrane-bound aminopeptidase, identified as a functional receptor for SARS-CoV-2 \[[@CR10]\]. The spike protein of SARS-CoV-2 binds to ACE2 and those trigger the infection which is highly expressed in lungs and heart \[[@CR10]\]. The angiotensin II converted from angiotensin I by ACE, responsible for vasoconstriction, increased blood pressure and vascular remodeling. Clinical observation revealed significant elevation of plasma angiotensin II in a patient with COVID-19, which suggests that binding of COVID-19 to ACE2 causes a release of excessive angiotensin II through the renin-angiotensin system (RAS), increasing heart loading, cardio-myocyte hypertrophy, and high blood pressure \[[@CR1]\]. Invasion of the virus to the lung surface cells and cardio-myocytes causes inflammation and release of pro-inflammatory cytokines such as interleukin (IL) 1--6, tumor necrosis factor, interferon, endothelial adhesive factor, granulocytes colony-stimulating factor, chemoattractant protein 1, by the over-activating immune response of the body and increased apoptosis of myocardial cells which enhance the risk of cardiovascular events \[[@CR1]\]. Besides the activity of pro-inflammatory cytokines, the myocardial dysfunction could be caused by severe lung failure because of the infection and reduced the amount of oxygen supply or hypoxemia \[[@CR12]\].

CVD Complications Associated with COVID-19 {#Sec5}
==========================================

Myocardial Injury and Myocarditis {#Sec6}
---------------------------------

A study performed on 53-year-old white women without any previous history of CVD, admitted to hospital with COVID-19 infection and found to have severe left ventricular dysfunction \[[@CR3]\]. Increased levels of cardiac troponin were observed in that patient which is identified as a sensitive marker for myocardial injury and the cardiac magnetic resonance imaging (MRI) analysis showed to have diffuse edema and acute myocarditis. Moreover, the study suggests that the onset of symptoms a couple of days after influenza-like syndrome indicates potential myocyte dissemination of the virus, therefore, the onset of heart failure \[[@CR3]\]. Association between COVID-19 infection and the myocardial injury was first reported in Wuhan, China, in a study of 41 patients with the disease, among which 12% of patients had a high sensitivity troponin I above the threshold of 28 pg/ml \[[@CR7]\]. According to the report of the National Health Commission of China, in patients who died from COVID-19, 11.8% of them were without prior CVD; furthermore, those patients had substantial heart damage and elevated level of troponin. Virus infections such as influenza and parvovirus B-19 are described as one of the most common causes of myocarditis \[[@CR3]\]. Though the exact mechanism behind myocardial injury induced by SARS-CoV-2 is not fully understood, a previous report revealed the presence of the SARS-CoV genome in the heart of 35% of patients with the infection, which raises the possibility of direct damage of cardiomyocytes by the virus \[[@CR12]\]. As both SARS-CoV and SARS-CoV-2 are highly homologous in the genome, they may have the same pathophysiology. Some other mechanism suggests direct myocardial involvement via ACE2 \[[@CR11]\]. Studies also report that cytokine storm in patients with COVID-19, due to the imbalance between subtypes of T helper cells, may contribute to myocardial injury \[[@CR12]\].

Cardiomyopathy and Acute Heart Failure {#Sec7}
--------------------------------------

A study reported that heart failure is an initial presentation of COVID-19 in 23% of patients, with cardiomyopathy in 33% of patients \[[@CR7]\]. According to another study, 24% of patients had heart failure, and nearly half of those patients did not have any known history of CVD or hypertension. As heart failure could occur due to exacerbation of prior left ventricular dysfunction, the occurrence of new cardiomyopathy in those patients remains unclear \[[@CR9]\].

Venous Thromboembolism {#Sec8}
----------------------

Due to excessive inflammation, immobilization, and diffuse intravascular coagulation (DIC), COVID-19 may lead to venous thromboembolism \[[@CR13]\]. Studies revealed significant abnormalities in the coagulation pathway in patients with COVID-19, along with elevated D-dimer \[[@CR7]\]. A study performed on 184 intensive care unit (ICU) patients with COVID-19 pneumonia, where those patients received a standard dose of thromboprophylaxis, despite regular systemic thrombosis prophylaxis, 31% of those patients have thrombotic complications which are remarkably high and 27% of them have confirmed venous thromboembolic event (VTE) \[[@CR13]\]. A study suggests that anticoagulation therapy with low molecular weight heparin may reduce mortality in patients with severe COVID-19 infection \[[@CR7]\].

Cardiac Arrhythmias {#Sec9}
-------------------

Cardiac arrhythmia is another cardiovascular complication in patients with COVID-19 infection \[[@CR9]\]. A study revealed the presence of cardiac arrhythmias in 17% of hospitalized, and 44% of ICU patients infected with COVID-19 \[[@CR7]\]. However, a high prevalence of cardiac arrhythmias may arise from hypoxia, abnormal metabolism, neuro-hormonal, or inflammatory stress induced by COVID-19 infection.

COVID-19 and DM {#Sec10}
===============

Studies suggest that COVID-19-infected individuals with DM are at higher risk for developing complications including death \[[@CR14]\], though the association between diabetes and COVID-19-induced severe disease is not clear yet \[[@CR15]\]. However, COVID-19-infected individuals with diabetes have shown three times more fatality rate (7.3%) compared to those without diabetes (2.3%), reported by the Chinese Centre for Disease after studying 72,314 COVID-19 cases \[[@CR14]\].

Mechanism for the Severity of COVID-19 Infection in DM {#Sec11}
------------------------------------------------------

Individuals having DM are more susceptible to infections, especially influenza, and pneumonia; therefore pneumococcal and annual influenza vaccination has been recommended for individuals with diabetes (above 2 years of age) \[[@CR16]\]. This is because of their compromised immune system, particularly the innate immunity \[[@CR17]\]. Also, innate immunity may be affected temporarily by transient hyperglycemia in response to infection. Numerous factors such as hyperglycemia, altered production of cytokine, impaired T cell-mediated immune response, inhibition of neutrophil chemotaxis, ineffective microbial clearance, and phagocytic cell dysfunction may contribute to immune dysfunction in diabetic individuals, a possible mechanistic pathway of severity between COVID-19 and DM (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR18]\]. The hypothesis suggests that ACE2 may play a vital role in the severity of COVID-19 infection in diabetic individuals, as the virus utilize ACE2 for invading into host pneumocytes \[[@CR17]\] and ACE2 is also expressed in pancreatic tissue \[[@CR18]\]. Alongside, individuals with diabetes have been shown to have elevated levels of the pro-inflammatory cytokine, especially IL-1, IL-6, and tumor necrosis factor-α (TNF-α), and different markers such as C- reactive protein, D-dimer, and fibrinogen, those may further prolong the cytokine storms and lead to severe illness in diabetic individuals with COVID-19 infection; the role of the markers in COVID-19 is to induce DM (Fig. [3](#Fig3){ref-type="fig"}) \[[@CR17]\].Fig. 2A possible mechanistic pathway of association between DM and COVID-19Fig. 3Role of different marker in COVID-19 to induce DM and their severity

Significant increase in infection and replication of influenza virus after pulmonary endothelial cells being exposed to elevated concentration of glucose in vitro, indicating increased viral replication in hyperglycemic condition. Therefore, hyperglycemia may also play a role in the pathogenesis and prognosis of respiratory viral diseases, though further study needed to conclude this matter \[[@CR14]\]. Elevated levels of glucose may also suppress the immune response against the virus. According to experimental data, glycemic control can be beneficial clinically in patients who are having both diabetes and respiratory viral infection, like COVID-19 \[[@CR14]\].

Medication-Related Risk Factors in Diabetic Individuals with COVID-19 {#Sec12}
---------------------------------------------------------------------

The SARS-CoV-2 virus attaches to the ACE2 enzyme at low cytosolic pH and invades into the cell, leading infection \[[@CR19]\]. Angiotensin II has a strong role in pH alkalizing. Angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blockers (ARBs) reduce the levels of angiotensin II and cause low cytosolic pH \[[@CR19]\]. Therefore, diabetes patients who are treated with ACEI and ARBs have shown to have elevated expression of ACE2 and those people have a higher chance to develop severe and fetal COVID-19 infection \[[@CR20]\]. A study reported hypoglycemia in a 26-year-old patient with type 1 diabetes after being treated with chloroquine phosphate (500 mg) for 4 consecutive weeks \[[@CR21]\]. The use of chloroquine is very frequent in COVID-19-infected patients; therefore, the infected patients with type 1 diabetes should be monitored closely as hypoglycemia could be associated with the increased risk of mortality in those patients. A previous study on SARS-CoV patients without previous diabetes demonstrated pancreatic damage in 51.28% of patients, leading to acute type 1 diabetes mellitus during hospitalization \[[@CR14]\]. This may also be possible in patients with COVID-19 infection, though further evidence is required to conclude this. Alongside, dipeptidyl peptidase-4 (DPP-4) is shown to be the primary receptor of MERS-CoV and there is a chance that the DPP-4 receptor may act as a receptor for COVID-19 infection which is important to explore as DPP-4 inhibitors are widely used in the treatment of diabetes mellitus \[[@CR14]\].

Conclusion {#Sec13}
==========

Both the individuals with prior CVD and diabetes are at higher risk to develop severe COVID-19 infection. Alongside, development of CVD complications mostly myocardial injury, cardiomyopathy, venous thromboembolism, and cardiac arrhythmias among the individuals without prior CVD, is also an emerging concern. In diabetic individuals, there are some medications such as ACEI, ARBs, chloroquine, and DPP-4 inhibitors using issues that also arise as some study predicts; their use could worsen the conditions of the patients with COVID-19 which call for the careful use of those medications in diabetic individuals with the infection. Lastly, as the number of infections increasing day by day, it is quite predictable to increase the number of those complicated cases as well. Therefore, medical professional needs to be aware and prepare for managing those emergencies effectively.
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